Back to Awarded Treatment Trials
Awarded Trial: 98-RC-304
Grant ID
98-RC-304
Illness
Bipolar Disorder and Schizophrenia
Primary Drug/Intervention
Mifepristone
Primary Dosage
200 mg/day
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Young
Sample Size
20
Duration of Study Period for Each Subject
1 week
Outcome Measurements
HAM-D. PANSS
Results
In patients with bipolar depression, mifepristone produced a significant reduction in HAM-D scores compared to placebo. A significant effect was also observed on neuropsychological tests of executive function. Twenty patients with schizophrenia also received mifepristone in a blinded crossover design for one week. No significant effects were observed on any measure of neurocognitive function or symptom ratings. (For further details: Gallagher P. et al., Effects of adjunctive mifepristone (RV-486) administration on neurocognitive function and symptoms on schizophrenia. Biological Psychiatry 57:155-161, 2005.
Publication
Young AH et al., Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 29:1538-1545, 2004)
Link
N/A
PI Name
Allan Young
Degree
MBChB,
Center
N/A
Institution
University of Newcastle Upon Tyne
Address
6 Kensington Terrace
City or Town
Newcastle Upon Tyne
State or Province
N/A
Zip or Postal Code
NE1 7RU
Country
United Kingdom
Email Address
a.h.young@newcastle.ac.uk